Published in Ann Intern Med on August 05, 2008
Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med (2009) 2.85
Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ (2013) 2.31
Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology (2011) 1.21
The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen" should shape clinical practice. BMC Med (2015) 1.01
Prostate cancer: Personalized risk - stratified screening or abandoning it altogether? Nat Rev Clin Oncol (2016) 1.00
The value of personalised risk information: a qualitative study of the perceptions of patients with prostate cancer. BMJ Open (2013) 0.92
Developing and validating a scoring tool for identifying people who inject drugs at increased risk of hepatitis C virus infection. BMJ Open (2012) 0.78
Risk prediction versus diagnosis: preserving clinical nuance in a binary world. Ann Intern Med (2009) 0.75
Risk prediction versus diagnosis: preserving clinical nuance in a binary world. Ann Intern Med (2009) 0.75
Validation of EGCRISC for Chronic Hepatitis C Infection Screening and Risk Assessment in the Egyptian Population. PLoS One (2016) 0.75
Risk prediction versus diagnosis: preserving clinical nuance in a binary world. Ann Intern Med (2009) 0.75
Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit. PLoS One (2016) 0.75
Models for estimating the metabolic syndrome biological age as the new index for evaluation and management of metabolic syndrome. Clin Interv Aging (2017) 0.75
Risk prediction versus diagnosis: preserving clinical nuance in a binary world. Ann Intern Med (2009) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med (2008) 3.32
Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ (2006) 2.03
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke (2003) 1.36
Clinical problem solving. A hand-carried diagnosis. N Engl J Med (2007) 1.15
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol (2003) 5.20
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol (2005) 2.98
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg (2004) 2.84
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2005) 2.69
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2008) 2.57
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology (2005) 2.49
The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol (2008) 2.39
Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (2007) 2.36
A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol (2005) 2.30
Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. J Urol (2006) 2.30
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer (2009) 2.18
Meta-analysis: Its strengths and limitations. Cleve Clin J Med (2008) 2.15
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
Therapeutic applications of fenugreek. Altern Med Rev (2003) 2.12
Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst (2003) 2.11
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol (2004) 2.01
Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res (2008) 1.96
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin (2012) 1.94
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol (2002) 1.88
The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care (2012) 1.84
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol (2005) 1.83
Predicting 6-year mortality risk in patients with type 2 diabetes. Diabetes Care (2008) 1.81
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol (2009) 1.81
An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med (2007) 1.80
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol (2006) 1.76
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol (2006) 1.73
Prostate cancer nomograms: an update. Eur Urol (2006) 1.71
The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int (2007) 1.71
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70
Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys (2007) 1.69
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol (2009) 1.69
A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med (2010) 1.64
Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology (2005) 1.63
Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol (2007) 1.63
Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol (2008) 1.61
Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. Eur Urol (2007) 1.60
Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol (2008) 1.60
Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials (2007) 1.58
Critical review of prostate cancer predictive tools. Future Oncol (2009) 1.57
A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol (2007) 1.57
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol (2004) 1.55
The association of community health indicators with outcomes for kidney transplant recipients in the United States. Arch Surg (2012) 1.53
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol (2004) 1.52
A model for predicting the risk of de novo stress urinary incontinence in women undergoing pelvic organ prolapse surgery. Obstet Gynecol (2014) 1.52
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy. Eur Urol (2011) 1.50
Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecol Oncol (2012) 1.48
Nomogram to predict seminal vesicle invasion using the status of cancer at the base of the prostate on systematic biopsy. Int J Urol (2010) 1.47
Does mechanical bowel preparation ameliorate damage from rectal injury in radical prostatectomy? Analysis of 151 rectal injury cases. Int J Urol (2013) 1.47
Achieving optimal outcomes after radical prostatectomy. J Clin Oncol (2005) 1.46
Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest (2011) 1.46
Comparative analysis of three risk assessment tools in Australian patients with prostate cancer. BJU Int (2011) 1.46
Reliability of adverse symptom event reporting by clinicians. Qual Life Res (2011) 1.45
Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res (2004) 1.45
Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol (2005) 1.45